FrançaisSabra Health Care REIT (SBRA): financial analysis & fundamentals
📈 See the interactive version (live chart) →
Valuation & profitability
| Metric | Value | What it means |
|---|---|---|
| P/E (price / earnings) | 79.6 | The higher, the more growth the market expects. |
| Forward P/E | 26.7 | On next year's expected earnings. Lower than current P/E = rising earnings. |
| PEG (P/E ÷ growth) | — | Below 1 = cheap given growth; above 2 = expensive. |
| Net margin | 8% | Share of revenue that ends up as profit. |
| Revenue growth | 25% | Pace of revenue growth. |
| Price-to-book | 1.9 | Price relative to book value. |
| Market cap | $5.3 B | Total market value of the company. |
| Dividend yield | 6.10% | Annual dividend ~$1.20/share relative to price. |
Income statement (by year)
| Year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2022 | $625 M | $-78 M | -12% |
| 2023 | $648 M | $14 M | 2% |
| 2024 | $703 M | $127 M | 18% |
| 2025 | $775 M | $156 M | 20% |
📊 Open the interactive Sabra Health Care REIT page (charts, live news) →
Frequently asked questions
Is Sabra Health Care REIT stock expensive?
Sabra Health Care REIT has a P/E of 79.6 (forward P/E 26.7) and a PEG of —. A PEG below 1 is rather cheap given growth, above 2 is expensive. Verdict: valuation to review.
What is Sabra Health Care REIT's net margin?
Sabra Health Care REIT's net margin is about 8% — the share of revenue that ends up as net profit.
What is Sabra Health Care REIT's revenue?
Latest known revenue: $775 M for net income of $156 M. The year-by-year breakdown is in the income statement above.
What is Sabra Health Care REIT's market cap?
Sabra Health Care REIT (SBRA) has a market cap of about $5.3 B.
Does Sabra Health Care REIT pay a dividend?
Yes: Sabra Health Care REIT pays about $1.20/share per year, i.e. roughly a 6.10% yield at the current price.
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Data: Yahoo Finance, recomputed by JPI Invest. A stock can be « cheap » for a bad reason.